KBP 042

Drug Profile

KBP 042

Alternative Names: DACRA; DACRA 042; KBP042

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KeyBioScience
  • Developer KeyBioScience; Nordic Bioscience
  • Class Insulin sensitisers; Peptides
  • Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Metabolic disorders; Type 2 diabetes mellitus

Most Recent Events

  • 23 Aug 2017 Phase-II clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in Denmark, Czech Republic (SC) (NCT03230786) (EudraCT2017-001061-24)
  • 28 Jul 2017 KeyBioscience plans a phase II trial for Type-2 diabetes mellitus (Adjunctive treatment) (SC) (NCT03230786)
  • 09 Jun 2017 Pharmacodynamics data from a preclinical trial in Metabolic disorders presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top